Led · Equity · May 2023

Prognos Health is a New York City–based real-world data (RWD) company operating a managed, integrated RWD marketplace. Its platform harmonizes lab and health records across more than 325 million de-identified patients to provide a comprehensive, integrated view of patient health. The marketplace is used by over 70 life sciences customers to accelerate drug development, improve the safety and efficacy of existing drugs, and identify new patient populations. Led by CEO Sundeep Bhan, Prognos serves researchers, payers, and providers with fully integrated datasets to support clinical and commercial decision-making. The company raised $23M in growth equity and intends to use the funds to accelerate growth and expand the reach of its platform. The article emphasizes the company’s focus on expanding its impact on healthcare through data-driven tools and partnerships. Medivo operates a HIPAA-compliant, cloud-based health monitoring platform that provides modules for physicians and patients across a range of conditions and offers mobile tools and simple explanations of lab results. The company provides free services for physicians and consumers and has expanded its reach with increased engagements with life sciences firms and a partnership with the American Association of Clinical Endocrinologists. Medivo reports having doubled its growth year-over-year for the past three years and has presented peer-reviewed findings from a proprietary clinical database. The platform includes modules for diabetes, dyslipidemia, hepatitis C, gout, low testosterone, irritable bowel disease, hereditary angioedema, chronic myelogenous leukemia and other conditions, with initiatives to add obesity, rheumatoid arthritis, hepatitis B, HIV, several cancers, and additional chronic diseases. The company plans to continue expanding its network of laboratories, enrich its analytics services, build connectivity to additional data sources, and broaden product offerings and patient engagement services. Medivo is New York City–based and is venture-backed by investors including Merck GHIF, Safeguard Scientifics, and MentorTech Ventures. Medivo provides data analytics and lab testing services through an online, HIPAA‑compliant platform that connects patients to a nationwide network of physicians, lab service centers, and home testing services. Its PatientPath™ services identify gaps in patient lab testing and treatment, enable testing through thousands of labs, explain results to patients, and relay information to primary care physicians. The platform is designed to improve access to testing, educate patients about results, and help physicians make more efficient use of diagnostic testing. Medivo’s stated mission is to save lives through faster and easier access to quality healthcare; the company is led by co‑founder and CEO Sundeep Bhan. The article positions Medivo to capitalize on a U.S. lab testing market described as more than $50 billion and expected to double by 2020, noting lab services affect roughly 70% of critical clinical decisions. The company announced a $7 million Series A to support product development and expansion of sales and marketing.

Participated · Equity · Jul 2022

Syapse combines clinical expertise with smart technologies to transform data into evidence and experience in collaboration with a network of partners. The company is led by CEO Ken Tarkoff and is based in San Francisco and New York. Its core offering includes a Learning Health Network that partners with community health systems to support precision medicine strategies aimed at improving clinical outcomes, reducing costs, and enhancing patient experience. Syapse has also added life sciences partnerships with established biopharmaceutical companies. The company raised $35M in Growth funding and intends to use the funds to expand its focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer. Syapse provides real-world evidence (RWE) and actionable treatment insights through its Syapse Learning Health Network to improve outcomes for people with cancer. The platform standardizes and normalizes de-identified clinical and molecular data across participating healthcare providers to support clinical decisions and research. Syapse has expanded partnerships with community health systems and life sciences companies and has collaborated with the FDA to address urgent public health challenges, including COVID-19. The company positions its network to drive precision medicine strategies that aim to improve clinical outcomes, reduce costs, and enhance patient experience. The announced financing is intended to expand partnering opportunities with life sciences, health systems, regulators, and molecular labs to deliver more real-world insights. Syapse works with leading health systems, life sciences companies, and regulators to accelerate the creation and use of real-world evidence to improve cancer patient outcomes. The company provides insights from real-world data through a portfolio of products that support research and product development, clinical trial patient matching, regulatory filings, and monitoring of commercially approved products. Syapse integrates clinical, molecular, and outcomes data to support large‑scale precision medicine programs at health systems. Its Syapse Learning Health Network is described in the press release as one of the world’s largest networks dedicated to improving outcomes in cancer care through precision medicine. The company recently presented collaborative research with the FDA Office of Clinical Pharmacology and Advocate Aurora Health on pneumonitis incidence at the AACR annual meeting, illustrating its RWE capabilities. Proceeds from the announced financing are intended to accelerate the creation and use of real‑world evidence in oncology and support Syapse’s ongoing collaborations and product development. Syapse develops an oncology software platform and the Syapse Data Sharing Network to enable physicians to view treatments and outcomes for patients across the country and apply that information to improve care. Led by CEO Ken Tarkoff and based in San Francisco, the company sells its platform to large health systems and lists customers including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health. Syapse recently raised $30m in Series D financing. The company intends to use the funds to expand operations and bring its solutions to more providers and their cancer patients. Its core product focuses on enabling consistent precision-medicine practice across large health systems by connecting treatment and outcome data. The Data Sharing Network is positioned as a clinical-data tool to inform treatment decisions across participating institutions. Syapse provides cloud-based precision medicine software to academic and community health systems to support widespread adoption of precision oncology. The platform integrates clinical, genomic, and other molecular data from medical records, labs, and pharmacies to create a longitudinal patient profile. It offers guidance on diagnostic and therapeutic strategy based on clinical best practices and supports implementation of treatment decisions while coordinating care across geographically dispersed teams. The software also measures patient outcomes to learn what works and improve best practices. Led by CEO Glenn Winokur and based in Palo Alto, Syapse intends to use new funding to expand adoption of its software in community health systems. The company completed the first close of a Series C financing as reported in December 2016.

Participated · Series B · Jun 2022

Moxe Health is an interoperability company that enables secure, automated exchange of clinical data between healthcare providers and health plans through direct integration with electronic health records. Its API-first, EHR-agnostic architecture eliminates manual record-retrieval tasks, lowering administrative burden for providers and delivering structured, ready-to-use data to payers. The platform spans acute, ambulatory, independent, and specialty practices, giving it a broad and growing nationwide network. Providers retain governance and participation controls, ensuring transparency and trust in data sharing while reducing staff workload and requestor abrasion. Health plans benefit from immediate, consistent access to high-quality member data that supports critical operational and quality workflows. With new backing from BV Investment Partners, the company intends to accelerate network expansion, deepen embedded EHR relationships, and continue investing in technology that simplifies data exchange at scale.

Participated · Equity · Jun 2022

Moxe offers 100% digital, API-first clinical data exchange solutions that digitize medical charts and enable bidirectional, secure information flow between providers, payers, and third-party requestors. Its platform is compatible with leading EHRs and supports use cases including risk adjustment, quality improvement, payment integrity, and care management. The company reported record growth: its network nearly doubled in the last year and it currently serves payers representing 75 million lives, leading third-party requestors, and more than 60 hospital systems. Moxe will use the new funding to prioritize team expansion and technology investments to further advance its clinical data exchange capabilities. As part of the round, Tom Schnettler and Kirk Nielsen joined Moxe’s board. The company positions itself to improve payer-provider collaboration, eliminate administrative waste, and put actionable insights directly into the clinical workflow. Madison, Wis.-based Moxe provides a clinical data clearinghouse that connects directly to all major EMR systems to enable granular extraction of complete clinical records and real-time, bi-directional sharing of clinical data. Its platform automates requests for information while enforcing release restrictions to ensure minimum necessary PHI release, supporting use cases such as risk adjustment, HEDIS and Star ratings, and regulatory compliance. The company says its network of payer and provider organizations together insure more than 50 million Americans and deliver tens of millions of annual visits. Moxe announced it has secured an additional round of capital to fuel commercial and product expansion and to scale its team, particularly in commercial, product, and engineering. The company reported it has released new products to simplify Release of Information and streamline collaboration around open care, risk, and quality gaps and claims to have saved clients tens of millions of dollars. Moxe frames the funding as positioning it to lead on payer-provider interoperability amid growing regulatory focus on standards-based APIs.

Participated · Series C · Jan 2019

Trice Medical develops a portable, tablet-based imaging platform that combines a disposable needle camera (mi-eye™) with a high-quality ultrasound transducer (mi-ultra™) for orthopedic procedures. The company’s products are intended to enable procedures outside of traditional imaging suites. Since 2019, Trice has acquired Seg-WAY™ Orthopedics and Tenex Health, expanding its capabilities in minimally invasive ultrasonic technology for chronic pain treatment. The company is led by CEO and President Mark Foster. Trice announced a Series D financing whose amount was not disclosed and entered a strategic arrangement with Bioventus as part of the transaction. As described in the articles, Trice and Bioventus will pursue co-development to explore integration of their technologies to accelerate adoption of both companies’ offerings. Trice Medical, based in Malvern, Pa., makes integrated, camera-enabled and ultrasound platforms for minimally invasive orthopedic diagnostics, including the mi-eye 2 disposable arthroscopy camera and the mi-ultra 15 MHz handheld ultrasound transducer. The company’s Dynamic Imaging Platform combines the mi-eye technology with the mi-ultra on a single portable platform. Trice says its mission is to provide more immediate and definite patient care, reduce false reads from indirect modalities, and significantly lower healthcare costs. The company plans to expand worldwide commercialization of mi-eye 2 and mi-ultra and to accelerate development of its minimally invasive product portfolio. Management described 2019 as a transformational year, with plans to expand sales globally, launch several new products and announce large multinational partnerships. Trice Medical, based in King of Prussia, Pa., has developed the mi-eye2, a fully integrated camera-enabled handheld diagnostic scope that lets physicians diagnose joint injuries from the office. The mi-eye2 uses a disposable needle embedded with a wide-angle camera lens and improved vision quality to provide a non-invasive, more complete diagnosis. The device is currently being used by nearly 100 physician practices across 25 states. The company intends to use recent funding to accelerate and expand U.S. market penetration, support R&D, and grow sales and marketing. Trice Medical also plans to pursue key international regulatory approvals. Jeffrey O’Donnell, Sr. serves as President and CEO. The company has raised $40.9M to date. Trice Medical develops micro-invasive diagnostic tools for in-office procedures. Its core product, the mi-eye, is a fully disposable, single-use visualization device that uses a standard 14-gauge needle with an integrated camera and light to perform diagnostic arthroscopy during the initial consultation. An LCD tablet running Android OS attaches via a data cable to display images from the mi-eye needle. The company closed an $18.1M Series B financing led by HealthQuest Capital. Following the round, Trice appointed Craig Carra as its newly created Chief Financial Officer. Carra is a medical device and services veteran with roughly 20 years of experience and prior roles at Coopers & Lybrand, Surgical Laser Technologies, PhotoMedex and Ella Health. Trice Medical's core product, mi-eye, is a fully disposable, single‑use visualization device that integrates a camera and light source into a standard 14‑gauge needle to perform diagnostic arthroscopy in the physician's office. The device connects via a data cable to a separate Android‑based LCD tablet and is delivered sterile and ready for immediate use. Trice positions mi-eye to provide faster, more definitive, and less expensive diagnoses by eliminating false reads from indirect modalities such as MRI. The company received FDA 510(k) clearance for mi-eye, which it described as a key regulatory milestone. Trice plans to apply for CE Mark in Europe and seek approvals in other countries, and intends a limited marketing launch beginning in Q4 2014 while building inventory and developing marketing and educational programs. Financially, the company received the balance of cash related to an $11.6M Series B financing led by Safeguard Scientifics.